Fluoroquinolone is developed expressly for ophthalmic use

Article

Modern fluoroquinolones have evolved over more than 4 decades, from the parent quinolone compound, nalidixic acid (NegGram, Sanofi-Aventis US), patented in 1962. Since then, more than 10,000 derivatives have been patented, all with structural modifications that added features to improve systemic absorption, extend spectrum of action to include Gram-positive microorganisms, and reduce systemic toxicity.

Key Points

Modern fluoroquinolones have evolved over more than 4 decades, from the parent quinolone compound, nalidixic acid (NegGram, Sanofi-Aventis US), patented in 1962. Since then, more than 10,000 derivatives have been patented, all with structural modifications that added features to improve systemic absorption, extend spectrum of action to include Gram-positive microorganisms, and reduce systemic toxicity.

Notably, in 1973 the first fluoroquinolone antibiotics were identified, with the addition of a fluorine atom at position 6. Norfloxacin followed in 1978, ciprofloxacin in 1983, then ofloxacin and its l-isomer levofloxacin, and most recently, moxifloxacin and gatifloxacin, the latter two containing a methoxy group at position 8, which increased potency and activity against atypical microbes and some anaerobes as well.1, 2

'Respiratory fluoroquinolones'

Chlorinated fluoroquinolones

Trends in bacterial susceptibilities in ocular isolates should be closely monitored. Data from sources such as Ocular TRUST3 clearly show a change in susceptibilities of ocular isolates in recent years, with reduced bacterial susceptibility to many familiar fluoroquinolones. Although considered broad-spectrum, it is worthwhile noting that many fluoroquinolones had not shown reliable activity against methicillin-resistant Staphylococcus aureus (MRSA) or against microbes that were classified as fluoroquinolone-resistant. Many bacterial isolates that were considered resistant to ciprofloxacin, including S. aureus and some streptococci, were not likely to be susceptible, even to newer-generation agents.4

In the 1990s, a subgroup of fluoroquinolones was noted to have particularly strong activity against Gram-positive microorganisms and against many resistant strains as well. These were the fluoroquinolones with a halogen atom, either fluorine or chlorine, at the C8 position. The agents were associated with increased potency, lower bacterial minimum inhibitory concentrations, slower development of bacterial resistance mediated by increased DNA gyrase mutations, and increased efficacy against MRSA, methicillin-resistant S. epidermidis, and fluoroquinolone- or ciprofloxacin-resistant strains.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
© 2025 MJH Life Sciences

All rights reserved.